Welcome to Dx Digest, where FierceMedicalDevices highlights the highs and sometimes lows of the past week in the diagnostics industry. Foundation Medicine got a patent for its cancer genomic sequencing technology, and now it's using that patent to sue one of its rivals in the liquid biopsy market. Becton Dickinson scored European approval for its test for vaginal bacterial infections. Last but certainly not least, 10x Genomics released a new system for long-range genomic profiling. Read on for the details. And as always, feel free to contact us with any comments or questions. -- Emily Wasserman (email | Twitter ) Foundation Medicine wages patent war against Guardant Health over liquid biopsy tech Earlier this week, Foundation Medicine ($FMI) revealed that it got a patent for its cancer genomic sequencing technology. The company is planning to "evaluate strategies to maximize the value of this patent" and other intellectual property, CEO Michael Pellini said in a statement.